MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.amjcard.2021.07.005

Медицинская библиотека · The American journal of cardiology · 2021

Benefit of Extended Dual Antiplatelet Therapy Duration in Acute Coronary Syndrome Patients Treated with Drug Eluting Stents for Coronary Bifurcation Lesions (from the BIFURCAT Registry).

De Filippo Ovidio, Kang Jeehoon, Bruno Francesco, Han Jung-Kyu, Saglietto Andrea, Yang Han-Mo, Patti Giuseppe, Park Kyung-Woo, Parma Radoslaw, Kim Hyo-Soo, De Luca Leonardo, Gwon Hyeon-Cheol, Iannaccone Mario, Chun Woo Jung, Smolka Grzegorz, Hur Seung-Ho, Cerrato Enrico, Han Seung Hwan, di Mario Carlo, Song Young Bin, Escaned Javier, Choi Ki Hong, Helft Gerard, Doh Joon-Hyung, Truffa Giachet Alessandra, Hong Soon-Jun, Muscoli Saverio, Nam Chang-Wook, Gallone Guglielmo, Capodanno Davide, Trabattoni Daniela, Imori Yoichi, Dusi Veronica, Cortese Bernardo, Montefusco Antonio, Conrotto Federico, Colonnelli Iacopo, Sheiban Imad, de Ferrari Gaetano Maria, Koo Bon-Kwon, D'Ascenzo Fabrizio

СтатьяМногоцентровое исследованиеПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

Optimal dual antiplatelet therapy (DAPT) duration for patients undergoing percutaneous coronary intervention (PCI) for coronary bifurcations is an unmet issue. The BIFURCAT registry was obtained by merging two registries on coronary bifurcations. Three groups were compared in a two-by-two fashion: short-term DAPT (≤ 6 months), intermediate-term DAPT (6-12 months) and extended DAPT (>12 months). Major adverse cardiac events (MACE) (a composite of all-cause death, myocardial infarction (MI), target-lesion revascularization and stent thrombosis) were the primary endpoint. Single components of MACE were the secondary endpoints. Events were appraised according to the clinical presentation: chronic coronary syndrome (CCS) versus acute coronary syndrome (ACS). 5537 patients (3231 ACS, 2306 CCS) were included. After a median follow-up of 2.1 years (IQR 0.9-2.2), extended DAPT was associated with a lower incidence of MACE compared with intermediate-term DAPT (2.8% versus 3.4%, adjusted HR 0.23 [0.1-0.54], p <0.001), driven by a reduction of all-cause death in the ACS cohort. In the CCS cohort, an extended DAPT strategy was not associated with a reduced risk of MACE. In conclusion, among real-world patients receiving PCI for coronary bifurcation, an extended DAPT strategy was associated with a reduction of MACE in ACS but not in CCS patients.

Для цитирования: De Filippo Ovidio, Kang Jeehoon, Bruno Francesco, Han Jung-Kyu, Saglietto Andrea, Yang Han-Mo, Patti Giuseppe, Park Kyung-Woo, Parma Radoslaw, Kim Hyo-Soo, De Luca Leonardo, Gwon Hyeon-Cheol, Iannaccone Mario, Chun Woo Jung, Smolka Grzegorz, Hur Seung-Ho, Cerrato Enrico, Han Seung Hwan, di Mario Carlo, Song Young Bin, Escaned Javier, Choi Ki Hong, Helft Gerard, Doh Joon-Hyung, Truffa Giachet Alessandra, Hong Soon-Jun, Muscoli Saverio, Nam Chang-Wook, Gallone Guglielmo, Capodanno Davide, Trabattoni Daniela, Imori Yoichi, Dusi Veronica, Cortese Bernardo, Montefusco Antonio, Conrotto Federico, Colonnelli Iacopo, Sheiban Imad, de Ferrari Gaetano Maria, Koo Bon-Kwon, D'Ascenzo Fabrizio. Benefit of Extended Dual Antiplatelet Therapy Duration in Acute Coronary Syndrome Patients Treated with Drug Eluting Stents for Coronary Bifurcation Lesions (from the BIFURCAT Registry).. The American journal of cardiology. 2021. DOI: 10.1016/j.amjcard.2021.07.005.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.